In addition, AZD1775 selectively sensitized p53-deficient cancer cells to radiotherapy, gemcitabine, carboplatin and cisplatin, compared with the isogenic wild-type line (Bridges et al. 2011; Hirai et al. 2009). Here, TP53 is linked to cancer.